[go: up one dir, main page]

CY1123633T1 - Ετεροκυκλικες ενωσεις και οι χρησεις αυτων - Google Patents

Ετεροκυκλικες ενωσεις και οι χρησεις αυτων

Info

Publication number
CY1123633T1
CY1123633T1 CY20201101184T CY201101184T CY1123633T1 CY 1123633 T1 CY1123633 T1 CY 1123633T1 CY 20201101184 T CY20201101184 T CY 20201101184T CY 201101184 T CY201101184 T CY 201101184T CY 1123633 T1 CY1123633 T1 CY 1123633T1
Authority
CY
Cyprus
Prior art keywords
heterocyclic compounds
omecamtib
mecarvil
preparation
methods
Prior art date
Application number
CY20201101184T
Other languages
English (en)
Inventor
Mingda Bi
Robert KUEHL
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123633(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CY1123633T1 publication Critical patent/CY1123633T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Παρέχονται ορισμένες φαρμακοτεχνικές μορφές ομεκαμτίβης μεκαρβίλης και μέθοδοι για την παρασκευή και χρήση αυτών.
CY20201101184T 2013-03-14 2020-12-15 Ετεροκυκλικες ενωσεις και οι χρησεις αυτων CY1123633T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785763P 2013-03-14 2013-03-14
PCT/US2014/027104 WO2014152236A1 (en) 2013-03-14 2014-03-14 Heterocyclic compounds and their uses

Publications (1)

Publication Number Publication Date
CY1123633T1 true CY1123633T1 (el) 2022-03-24

Family

ID=50549466

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191101080T CY1122695T1 (el) 2013-03-14 2019-10-15 Αλας toy omecamtiv mecarbil και διαδικασια για την παρασκευη αλατος
CY20201101184T CY1123633T1 (el) 2013-03-14 2020-12-15 Ετεροκυκλικες ενωσεις και οι χρησεις αυτων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20191101080T CY1122695T1 (el) 2013-03-14 2019-10-15 Αλας toy omecamtiv mecarbil και διαδικασια για την παρασκευη αλατος

Country Status (42)

Country Link
US (13) US9951015B2 (el)
EP (3) EP2968173B1 (el)
JP (5) JP6498658B2 (el)
KR (2) KR102374159B1 (el)
CN (3) CN108785265B (el)
AP (1) AP2015008789A0 (el)
AR (2) AR095542A1 (el)
AU (2) AU2014240049C1 (el)
BR (2) BR112015023417B1 (el)
CA (3) CA2902646C (el)
CL (1) CL2015002708A1 (el)
CR (1) CR20150549A (el)
CY (2) CY1122695T1 (el)
DK (2) DK2970123T3 (el)
EA (1) EA031185B1 (el)
ES (2) ES2837038T3 (el)
HK (4) HK1218080A1 (el)
HR (2) HRP20191728T1 (el)
HU (2) HUE052355T2 (el)
IL (2) IL240788B (el)
JO (1) JOP20140114B1 (el)
LT (2) LT2970123T (el)
MA (2) MA38399B2 (el)
ME (1) ME03566B (el)
MX (3) MX363347B (el)
MY (2) MY186048A (el)
NZ (1) NZ711225A (el)
PE (1) PE20151786A1 (el)
PH (2) PH12019500176B1 (el)
PL (2) PL2970123T3 (el)
PT (2) PT2968173T (el)
RS (2) RS61215B1 (el)
RU (1) RU2663663C2 (el)
SA (1) SA515361088B1 (el)
SG (2) SG11201507258PA (el)
SI (2) SI2968173T1 (el)
SM (2) SMT202000685T1 (el)
TN (1) TN2015000380A1 (el)
TW (1) TWI667026B (el)
UA (1) UA117011C2 (el)
UY (1) UY35449A (el)
WO (2) WO2014152236A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2862859T3 (en) 2004-06-17 2018-08-13 Cytokinetics Inc RELATIONSHIPS, COMPOSITIONS AND PROCEDURES
EA031185B1 (ru) 2013-03-14 2018-11-30 Эмджен Инк. Гетероциклические соединения и способы их применения
TWI790189B (zh) 2015-01-02 2023-01-21 美商梅拉洛伊卡公司 細菌組成物
AU2016282985B2 (en) * 2015-06-26 2021-07-29 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
TWI847144B (zh) * 2017-06-30 2024-07-01 美商安進公司 奧美卡替莫卡必爾的合成
LT3645002T (lt) 2017-06-30 2025-02-10 Amgen Inc. Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais
EA039850B1 (ru) * 2018-04-30 2022-03-21 Эмджен Инк. Синтез омекамтива мекарбила
PT3594199T (pt) 2018-07-09 2020-09-04 Amgen Inc 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação
US11608318B2 (en) 2018-07-12 2023-03-21 Assia Chemical Industries Ltd. Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
EP3837009A1 (en) 2018-08-17 2021-06-23 Amgen, Inc Salts and crystal forms of omecamtiv mecarbil
CN114007689B (zh) * 2019-03-12 2025-01-03 安进股份有限公司 心肌肌钙蛋白活化剂的多晶型物和共晶体
JP2022525102A (ja) * 2019-03-12 2022-05-11 アムジェン インコーポレイテッド 心臓トロポニン活性化因子の多形
WO2021053189A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220348543A1 (en) * 2019-09-19 2022-11-03 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220402874A1 (en) * 2019-10-09 2022-12-22 Dr. Reddy's Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
BR112022015457A2 (pt) 2020-02-10 2022-10-04 Amgen Inc Formulação de comprimido, método para tratar insuficiência cardíaca, uso de uma formulação de comprimido, e, processo para fazer uma formulação de comprimido
JP2022039996A (ja) * 2020-08-26 2022-03-10 アムジエン・インコーポレーテツド Ｍｃｌ－１阻害剤処方物
JP2024500616A (ja) 2020-11-12 2024-01-10 アムジェン インコーポレイテッド オメカムチブメカルビルの投与により心不全を処置する方法
WO2022177927A1 (en) * 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2788775B1 (fr) 1999-01-22 2001-04-13 Pf Medicament Nouvelles n-alcoyl-n-[1-(omega-(arylalcoyloxy)alcoyl] piperidin-4-yl]-4h-3,1-benzo(thia/oxa)zines-2-amines substituees, leur preparation et leur application en therapeutique
SK8572002A3 (en) 1999-12-23 2002-12-03 Pfizer Prod Inc Hydrogel-driven drug dosage form
GB0124455D0 (en) 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
WO2003032965A2 (en) 2001-10-17 2003-04-24 King Pharmaceuticals Research And Development, Inc Use of ace inhibitors for reducing type 2 diabetes in high risk patients
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
DK2862859T3 (en) 2004-06-17 2018-08-13 Cytokinetics Inc RELATIONSHIPS, COMPOSITIONS AND PROCEDURES
WO2007054975A1 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
PE20100742A1 (es) * 2005-11-15 2010-11-25 Glaxo Group Ltd Nuevos procedimientos y formulaciones
US20070161617A1 (en) 2005-12-15 2007-07-12 Morgan Bradley P Certain chemical entities, compositions and methods
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US7989455B2 (en) * 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
US7639112B2 (en) 2007-04-25 2009-12-29 Sony Corporation Fuse device with integrated switch
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
TW201006816A (en) * 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
WO2010040110A1 (en) 2008-10-03 2010-04-08 Pericor Therapeutics, Inc. Methods and compositions for treatment of acute heart failure
US9253433B2 (en) 2012-11-27 2016-02-02 International Business Machines Corporation Method and apparatus for tagging media with identity of creator or scene
CA2902424A1 (en) * 2013-03-14 2014-09-25 Amgen Inc. Heterocyclic compounds and their uses
EA031185B1 (ru) 2013-03-14 2018-11-30 Эмджен Инк. Гетероциклические соединения и способы их применения
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
AU2016282985B2 (en) 2015-06-26 2021-07-29 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
TWI847144B (zh) * 2017-06-30 2024-07-01 美商安進公司 奧美卡替莫卡必爾的合成
LT3645002T (lt) 2017-06-30 2025-02-10 Amgen Inc. Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais
PT3594199T (pt) 2018-07-09 2020-09-04 Amgen Inc 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação
US11608318B2 (en) 2018-07-12 2023-03-21 Assia Chemical Industries Ltd. Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
EP3837009A1 (en) 2018-08-17 2021-06-23 Amgen, Inc Salts and crystal forms of omecamtiv mecarbil
US20220042055A1 (en) 2018-12-18 2022-02-10 Amgen Inc. Method of reducing aromatic nitro compounds
US20220348543A1 (en) 2019-09-19 2022-11-03 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021053189A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220411374A1 (en) 2019-10-09 2022-12-29 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
US20220402874A1 (en) 2019-10-09 2022-12-22 Dr. Reddy's Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
WO2021136477A1 (zh) 2020-01-03 2021-07-08 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
BR112022015457A2 (pt) 2020-02-10 2022-10-04 Amgen Inc Formulação de comprimido, método para tratar insuficiência cardíaca, uso de uma formulação de comprimido, e, processo para fazer uma formulação de comprimido
JP2024500616A (ja) 2020-11-12 2024-01-10 アムジェン インコーポレイテッド オメカムチブメカルビルの投与により心不全を処置する方法
WO2022177927A1 (en) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
AU2022232919A1 (en) 2021-03-10 2023-10-19 Amgen Inc. Synthesis of omecamtiv mecarbil
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Also Published As

Publication number Publication date
PH12015501998A1 (en) 2016-01-11
US9988354B2 (en) 2018-06-05
JP2020125307A (ja) 2020-08-20
US20200277261A1 (en) 2020-09-03
PH12015501998B1 (en) 2016-01-11
UY35449A (es) 2014-09-30
CN105120844A (zh) 2015-12-02
US20200399221A1 (en) 2020-12-24
LT2970123T (lt) 2019-11-11
PL2968173T3 (pl) 2021-03-08
BR112015023417A2 (pt) 2017-07-18
SMT202000685T1 (it) 2021-01-05
IL240788B (en) 2020-09-30
PT2968173T (pt) 2020-12-18
JP2016519071A (ja) 2016-06-30
BR112015023417B1 (pt) 2023-10-17
US20180312469A1 (en) 2018-11-01
US20240217933A1 (en) 2024-07-04
JP6689942B2 (ja) 2020-04-28
PE20151786A1 (es) 2015-12-11
CA3147180A1 (en) 2014-09-25
HK1218544A1 (zh) 2017-02-24
PH12019500176B1 (en) 2023-08-11
AU2014239995B2 (en) 2018-07-26
HK1219484A1 (zh) 2017-04-07
EP2968173B1 (en) 2020-10-14
MX2021001231A (es) 2021-04-12
MY186048A (en) 2021-06-17
TN2015000380A1 (en) 2017-01-03
EP2968173A1 (en) 2016-01-20
WO2014152270A1 (en) 2014-09-25
HRP20191728T1 (hr) 2019-12-13
KR20150136063A (ko) 2015-12-04
US20180273479A1 (en) 2018-09-27
MY204971A (en) 2024-09-25
US20240317687A1 (en) 2024-09-26
CA2902436A1 (en) 2014-09-25
RS59536B1 (sr) 2019-12-31
LT2968173T (lt) 2021-03-25
US11384053B2 (en) 2022-07-12
CY1122695T1 (el) 2021-03-12
BR112015022857B1 (pt) 2022-10-25
SMT201900563T1 (it) 2019-11-13
US20140309235A1 (en) 2014-10-16
HK1218080A1 (zh) 2017-02-03
CN105209437B (zh) 2018-09-18
JP2022023891A (ja) 2022-02-08
TW201524507A (zh) 2015-07-01
DK2970123T3 (da) 2019-10-21
AU2014239995A1 (en) 2015-09-10
CR20150549A (es) 2016-01-04
JP2016513683A (ja) 2016-05-16
ES2837038T3 (es) 2021-06-29
AU2014240049B2 (en) 2018-07-19
HUE052355T2 (hu) 2021-04-28
PH12019500176A1 (en) 2020-11-04
US11884630B2 (en) 2024-01-30
KR102474467B1 (ko) 2022-12-05
CN108785265B (zh) 2024-10-08
AP2015008789A0 (en) 2015-10-31
US20200079736A1 (en) 2020-03-12
US20220153700A1 (en) 2022-05-19
EP3821882A1 (en) 2021-05-19
SA515361088B1 (ar) 2018-07-22
JP6966590B2 (ja) 2021-11-17
SG10201706656RA (en) 2017-09-28
CA2902646C (en) 2022-08-16
JP6498658B2 (ja) 2019-04-10
KR102374159B1 (ko) 2022-03-15
EA201591728A1 (ru) 2016-01-29
US12221417B2 (en) 2025-02-11
HK1218512A1 (zh) 2017-02-24
AR095542A1 (es) 2015-10-21
NZ711225A (en) 2020-06-26
US11472773B2 (en) 2022-10-18
RU2663663C2 (ru) 2018-08-08
MX2015012414A (es) 2016-04-25
DK2968173T3 (da) 2020-12-21
AU2014240049C1 (en) 2019-03-07
CN108785265A (zh) 2018-11-13
US10421726B2 (en) 2019-09-24
PL2970123T3 (pl) 2020-03-31
SG11201507258PA (en) 2015-10-29
IL241089B (en) 2019-10-31
CA2902646A1 (en) 2014-09-25
NZ750950A (en) 2020-09-25
MA38399A1 (fr) 2017-01-31
KR20220045014A (ko) 2022-04-12
AR129504A2 (es) 2024-09-04
SI2968173T1 (sl) 2021-04-30
MA44637A1 (fr) 2019-08-30
JP6783138B2 (ja) 2020-11-11
US11958809B2 (en) 2024-04-16
US9951015B2 (en) 2018-04-24
HUE046285T2 (hu) 2020-02-28
UA117011C2 (uk) 2018-06-11
EP2970123A1 (en) 2016-01-20
MA44637B1 (fr) 2021-04-30
MX363347B (es) 2019-03-20
JP7174132B2 (ja) 2022-11-17
PT2970123T (pt) 2019-10-28
JP2019059746A (ja) 2019-04-18
BR112015022857A2 (pt) 2017-07-18
US20200331859A1 (en) 2020-10-22
US20230044617A1 (en) 2023-02-09
US20160016906A1 (en) 2016-01-21
HRP20201967T1 (hr) 2021-03-05
US20240101517A1 (en) 2024-03-28
TWI667026B (zh) 2019-08-01
AU2014240049A1 (en) 2015-09-10
CN105209437A (zh) 2015-12-30
RU2015143643A (ru) 2017-04-18
MX2015012429A (es) 2016-04-07
EP2970123B1 (en) 2019-08-14
SI2970123T1 (sl) 2019-12-31
RS61215B1 (sr) 2021-01-29
MA38399B2 (fr) 2020-12-31
WO2014152236A1 (en) 2014-09-25
JOP20140114B1 (ar) 2021-08-17
CA3147180C (en) 2024-04-23
IL241089A0 (en) 2015-11-30
CL2015002708A1 (es) 2016-03-11
IL240788A0 (en) 2015-10-29
US20220298114A1 (en) 2022-09-22
ME03566B (me) 2020-07-20
EA031185B1 (ru) 2018-11-30
ES2750676T3 (es) 2020-03-26

Similar Documents

Publication Publication Date Title
CY1123633T1 (el) Ετεροκυκλικες ενωσεις και οι χρησεις αυτων
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
IL281863A (en) Pharmaceutical compositions comprising meloxicam
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
CO2017002532A2 (es) Indazoles sustituidos con bencilo como inhibidores de bub1
IL256260B (en) Treprostinil derivatives and compositions and uses thereof
HK1219957A1 (zh) 蛋白質/蛋白質相互作用的大環抑制劑
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
EP3164406C0 (en) BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
MX2016005631A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
HUE057734T2 (hu) Heterociklusos vegyületek és alkalmazásuk
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
MX2015012416A (es) Compuestos heterociclicos y sus usos.
DK3066089T3 (da) Substituerede n-acetyl-l-cysteinderivater og relaterede forbindelser
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
HUE040169T2 (hu) BAFF-ra és B7RPl-re specifikus fehérjék és alkalmazásuk
FI20135866L (fi) Mikrobiologinen keratiinin prosessointi
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
UY34739A (es) ?uso de compuestos y método para el control de enfermedades de los cereales?.
TH1601000571A (th) สารประกอบที่แสดงฤทธิ์ทางการรักษาและวิธีการใช้ของมัน
EP3224253A4 (en) Bis(sulfonamide) derivatives and their use as mpges inhibitors
TH1501005855A (th) อนุพันธ์เบนซิมิดาโซโลนที่เป็นสารยับยั้งโบรโมโดเมน(Benzimidazolone Derivatives as Bromodomain Inhibitors)